


IMAGE



Infographic: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia: the RADIANCE study

Imran H. Yusuf ^{1,2}✉, Christin Henein^{3,4} and Sobha Sivaprasad ⁴

© The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2023

Eye (2024) 38:28–30; <https://doi.org/10.1038/s41433-023-02392-4>

The study recruited individuals with visual impairment secondary to myopic CNV with greater than -6D of spherical equivalence and axial length >26 mm. In addition to the exclusions presented in the infographic, the study also excluded patients with a history of stroke, intraocular steroids or surgery 3 months prior to randomization. Both ranibizumab arms received sham PDT at baseline. In group 1, vision stabilisation was defined as no change in BCVA in the previous two monthly visits. In group 2, treatment was discontinued if there was no evidence of disease activity (absence of intraretinal or subretinal fluid on optical coherence tomography imaging, or leakage on fluorescein angiography).

Non-inferiority (<5 ETDRS letters) was assessed between groups 1 and 2 to determine the effect of retreatment criteria on vision at 6 months. A mean visual acuity value for the PDT group at 6 months is not presented in the paper. There were no reported cases of endophthalmitis, myocardial infarction or death during the study. CNV – choroidal neovascularisation; BCVA – best corrected visual acuity; ETDRS – early treatment diabetic retinopathy study; PRP – panretinal photocoagulation; VEGF – vascular endothelial growth factor; PDT – photodynamic therapy; PRN –pro re nata (i.e., as needed); AE – adverse events; SAE – serious adverse events.

¹Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK. ²Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Headley Way, Oxford OX3 9DU, UK. ³UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK. ⁴NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK. ✉email: Imran.yusuf@eye.ox.ac.uk


Received: 29 November 2022 Revised: 10 December 2022 Accepted: 13 January 2023

Published online: 21 April 2023

A Randomized Controlled Study of Ranibizumab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia: The RADIANCE study

Wolf et al, *Ophthalmology*, 2014. 121(3):682-92

Study Design International, randomized, double-masked, active treatment-controlled Phase 3 clinical trial



Results	Mean number of Ranibizumab injections to 12 months		
	4.6	3.5	2.4 [^]
			[^] 38/55 received Ranibizumab from month 3
	Mean BCVA change at 3 months (letters)		
	↑10.5*	↑10.6* <small>*P<0.0001 vs PDT group</small>	↑2.2
	Mean BCVA change at 6 months (letters)		
	↑11.9#	↑11.7# <small>#PRN treatment guided by VA criteria is non-inferior to PRN treatment guided by disease activity criteria (P<0.00001)</small>	
	Mean BCVA change at 12 months (letters)		
	↑13.8	↑14.4	↑9.3
	Adverse events: ocular / non-ocular		
	AEs: 46 / 48 SAEs: 1 / 6 n=106	AEs: 44 / 51 SAEs: 1 / 5 n=116	AEs: 16 / 19 SAEs: 0 / 0 n=38 who received Ranibizumab after month 3

Conclusion Ranibizumab treatment, irrespective of retreatment criteria, is superior to photodynamic therapy in the treatment of CNV secondary to pathologic myopia

Reference: Wolf et al., "RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia". *Ophthalmology*, 2014.121(3):682–92.

FUNDING

Medical Research Council UK (MR/R000735/1).

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Imran H. Yusuf.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Please note that the infographic is best viewed online.